Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Graid Technology Announces SupremeRAID SE Support for the NVIDIA GeForce RTX 5000 Series, Expanding High-Performance RAID for Workstations13.2.2025 11:00:00 CET | Press release
With Support for the NVIDIA® GeForce RTX™ 5090, 5080, 5070 Ti, 5070 and 5060, SupremeRAID™ SE Continues to Push the Boundaries of High-Performance Workstation Storage SANTA CLARA, CALIFORNIA / ACCESS Newswire / February 13, 2025 / Graid Technology, the leader in GPU-based RAID solutions, today announced that SupremeRAID™ SE now supports the entire NVIDIA® GeForce RTX™ 5000 series, delivering unparalleled RAID performance to high-end workstation users. With support for the GeForce RTX 5090, 5080, 5070 Ti, 5070, and 5060, professionals can leverage NVIDIA's most powerful GPUs to maximize NVMe SSD performance with exceptional efficiency and resilience.Graid Technology Announces SupremeRAID™ SE Support for the NVIDIA® GeForce RTX™ 5000 Series SupremeRAID™ SE is Graid Technology's bring-your-own-GPU RAID solution, designed for workstation users who demand high-speed data access, reliability, and flexibility. With support for the GeForce RTX 5000 series, users can take advantage of NVIDIA's
The Glimpse Group Reports Q2 Fiscal Year 2025 Financial Results - 50% Increase in Revenue and Positive EBITDA, Positive Cash Flow & Positive Net Income13.2.2025 08:15:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR)(FSE:9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, provided financial results for its second quarter fiscal year 2025 year, ended December 31, 2024 ("Q2 FY '25"). Business Commentary by President & CEO Lyron Bentovim Financial Summary: Q2 FY '25 revenue of approximately $3.17 million, reflecting: a) 52% increase compared to Q2 FY '24 (ending December 31, 2023) revenue of approximately $2.08 million, and b) 30% increase compared to Q1 FY '25 (ending September 30, 2024) revenue of approximately $2.44 million. The increase in both comparative periods was primarily driven by an increase in Spatial Core revenues, as well as growth in our other businesses. Gross Margin for Q2 FY ‘25 was approximately 64% compared to 68% for Q2 FY ‘24. The decrease was driven
Sadot Group Inc. Announces Appointment of Ms. Catia Jorge as New Chief Executive Officer13.2.2025 08:00:00 CET | Press release
BURLESON, TEXAS / ACCESS Newswire / February 13, 2025 / Sadot Group Inc. (Nasdaq:SDOT) ("Sadot Group" or the "Company") today announced the appointment of Ms. Catia Jorge as its new Chief Executive Officer, effective immediately. Ms. Jorge, a seasoned leader in the global agri-commodity sector, joins Sadot Group at a pivotal time, as the Company transitions to focusing on expanding its platform globally. Ms. Jorge will report to the Board of Directors and lead Sadot's strategic initiatives, global operations, and business growth efforts to maximize the Company's long-term potential. A highly regarded industry veteran, Ms. Jorge brings nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. She most recently served as Brazil Country Head and Vice President/Grains Business Head Latin America for Olam Agri, where she managed a $1.0 billion annual revenue portfolio. Prior to Olam, she held leadership roles at Cargill Agricola South America expo
Cleverbridge Appoints Markus Scheuermann as Chief Financial Officer12.2.2025 05:00:00 CET | Press release
Seasoned Finance Leader Brings 20+ Years of Expertise in Financial Strategy, M&A and Digital Transformation to Cleverbridge COLOGNE, GERMANY & CHICAGO, IL / ACCESS Newswire / February 12, 2025 / Cleverbridge, a leading provider of ecommerce and billing solutions for global software and SaaS companies, today announced the appointment of Markus Scheuermann as Chief Financial Officer, effective as of April 1, 2025.Markus Scheuermann Scheuermann is a seasoned senior executive with over 20 years of experience in financial strategy, business development, M&A, and digital transformation within high-performing technology organizations. Most recently, he served as Chief Financial Officer at Thinkproject Group and has previously held key leadership roles at HolidayCheck Group, Hubert Burda Media, eBay, and McKinsey & Company. Markus will report directly to Wendi Sturgis, Cleverbridge CEO, and be part of an executive leadership team that includes CRO Kevin Feagan, CTO Radu Immenroth, and CHRO Ale
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 202411.2.2025 11:45:00 CET | Press release
Uncertain outlook for 2025 as new immigration policies are implemented PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 11, 2025 / A new CGFNS International report indicates that a robust annual rate of nurse migration into the United States held steady in 2024 as healthcare systems continued to look to foreign-educated nurses to help address persistent staffing shortages.CGFNS International 2024 Nurse Migration Report However, in its 2024 Nurse Migration Report, the organization also said the current high rates were likely unsustainable amid persisting visa retrogression and caps on employment-based green cards for nurses, along with new immigration policies being implemented by the Trump Administration that will likely have further impact on visa availability and processing times. CGFNS, a global health workforce non-profit that verifies credentials of healthcare professionals for immigration authorities and state licensing boards, reported that in fiscal year 2024 it received
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom